头孢哌酮钠舒巴坦钠联合吸入布地奈德治疗慢性阻塞性肺疾病急性加重期患者的临床疗效评价

Clinical evaluation of cefoperazone sodium and sulbactam sodium com-bined with inhaled budesonide in treatment of patients with chronic ob-structive pulmonary disease

目的探讨头孢哌酮钠舒巴坦钠联合吸入布地奈德治疗慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)患者的临床疗效。方法将93例AECOPD患者按照随机数字法分为对照组(n=46)与观察组(n=47)。两组均首先给予抗感染、解痉、祛痰以及平喘等常规治疗方法。对照组在此基础上加以头孢哌酮钠舒巴他钠,观察组在对照组的基础上雾化吸入布地奈德。比较两组临床疗效。结果观察组临床总有效率为93.62%(44/47),显著高于对照组(73.91%,34/46)(P<0.05);观察组患者治疗后肺功能指标(FEV1、FEV1%预计值以及FEV1/FVC)均显著高于治疗前及对照组治疗后(P<0.05);两组患者治疗后血清PCT及CRP水平均显著低于治疗前,且观察组患者治疗后血清炎性因子水平均显著低于对照组患者治疗后(P<0.05);对照组不良反应总发生率为8.70%(4/46),观察组为8.52%(4/47),两组差异无统计学意义(P>0.05)。结论头孢哌酮钠舒巴坦钠联合吸入布地奈德治疗AECOPD患者的临床疗效显著,应在临床上进行推广及应用。

Objective To investigate the clinical efficacy of cefoperazone sodium and sulbactam sodium combined with inhaled budesonide in treatment of chronic obstructive pulmonary disease with acute exacerbation （AECOPD）. Methods 93 cases were randomly divided into control group（n=46） and observation group（n=47）. Both groups were first given anti- infective therapy, antispasmodic, expectorant and asthma ere conventional therapy. The control group was given cefop- erazone sodium and sulbaetam sodium treatment, observation group was given budesonide inhalation, the clinical effi- cacy were compared between two groups. Results The total effective rate of observation group was 93.62%（44/47）, sig- nificantly higher than the control group（73.91%, 34/46）（P〈0.05）; The pulmonary function indexes（FEV1, FEV1% and FEV1/FVC） in the observation group were significantly higher than those before treatment and the control group after treatment（P〈0.05）; after treatment, the serum PCT and CRP levels of two groups were significantly lower than before treatment, the observation group were significantly lower than the control group （P〈0.05）; The adverse reaction rate of control group was 8.70%（4/46）, the observation group was 8.52%（4/47）, the difference was not significant between the two groups（P〉0.05）. Conclusion Cefoperazone sodium and sulbactam sodium combined with inhaled budesonide in treatment of patients with AECOPD has significant clinical efficacy, should be the promotion and application in clinical practice.